The world of health and medicine has broken countless barriers over the last few scores. Life sciences companies have continued to invest significantly in their research of globally corroding diseases, drug molecules discovery and development, and closely monitored clinical trials, to create industry-approved blockbuster medicines. These drugs, gaining precision with time, are curing more diseases and giving patients a chance at better lives. The pharma journey, however, gets complicated with more in-depth clinical and genetic research, as companies continue to find themselves facing more significant ‘unknowns’ than ever before.
As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and evidence based studies. One example of such study is economic burden of inadequate symptom control.
As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and evidence based studies. One example of such study is the economic burden of disease.
At the PMSA annual conference, Axtria’s Sudeep Saha and Celgene’s Jennifer Maurer shared an approach that demonstrated how to use patient-level data in a robust way to estimate market opportunity and product penetration in the field of Oncology.
